small molecule

JUXTAPID

LOMITAPIDE MESYLATE

Loss of exclusivityAugust 2027latest FDA-listed patent expiry
CompanyCHIESI FARMACEUTICI SPA

Drug detail

Brand nameJUXTAPID
Active ingredientLOMITAPIDE MESYLATE
StrengthEQ 60MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
7932268August 2027use U-1316

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JUXTAPID patent cliff — loss of exclusivity August 2027 | CliffBio